Medindia

X

Reportlinker Adds US Diabetic Retinopathy Industry

Friday, June 25, 2010 Corporate News J E 4
Advertisement


NEW YORK, June 24 Reportlinker.com announces that a new market research report is available in its catalogue:

US Diabetic Retinopathy Industry

http://www.reportlinker.com/p0209269/US-Diabetic-Retinopathy-Industry.html

This report analyzes the US Market for Diabetic Retinopathy in US$ Million. Annual estimates and forecasts are provided for the period 2011 through 2015. The report profiles 40 companies including many key and niche players such as Allergan, Inc., AstraZeneca PLC., Eyetech, Inc., Fovea Pharmaceuticals SA, Genentech, Inc., Gene Signal, Isis Pharmaceuticals, Inc., Lpath, Inc., MacuSight, Inc., OM Pharma S.A, OPKO Health, Inc., Oxford BioMedica Plc., pSivida Corp., Quark Pharmaceuticals, Inc., Sanwa Kagaku Kenkyusho Co., Ltd., Sirnaomics, Inc., Suzuken Co., Ltd., and Vitreoretinal Technologies, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

DIABETIC RETINOPATHY MCP-6237

A US MARKET REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-3

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II. A US MARKET REPORT

1. MARKET OUTLOOK II-1

Incidence and Prevalence of Diabetic Retinopathy Continue to Rise II-1

Table 1: Diabetic Retinopathy Patient Prevalence in the US by

Diabetes Type: 2006-2015 (In Thousand Patients) (includes

corresponding Graph/Chart) II-2

Table 2: Diabetic Retinopathy Patient Prevalence in the US by

Age Group: 2006-2012 (includes corresponding Graph/Chart) II-2

Table 3: Diabetic Retinopathy Prevalence in Type-1 Diabetic

Patients in the US by Age Group: 2006-2012 (includes

corresponding Graph/Chart) II-3

Prevalence of Diabetes on the Rise II-3

Huge Unmet Needs Fuel Demand for Pharmacological Drugs II-3

Market Awaits First Approved Drug; Off-label Use Continues II-4

Diabetic Retinopathy Drug Market to Post Dramatic Growth II-4

Insulin - A Potential Therapy for Diabetic Retinopathy II-4

Additional Trials Delay Arxxant's Launch II-5

Lucentis Shows Promise in Diabetic Retinopathy Treatment II-5

Avastin and Lucentis to Compete on Price II-6

Pycnogenol Continues to Appeal to Researchers II-6

Robo4 Protein - A Potential Therapeutic for Diabetic Retinopathy II-7

Bevacizumab Bodes Potential As An Adjunct to Surgery PDR

Treatment II-7

2. DIABETIC RETINOPATHY DRUG CLASS - AN OVERVIEW II-8

DRUG CLASSES IN DIABETIC RETINOPATHY II-8

VEGF Inhibitors II-8

Pegaptanib II-8

Bevacizumab II-8

Ranibizumab II-8

PKC Inhibitors II-9

Corticosteroids II-9

Aldose Reductase - AGE Inhibitors II-10

Somatostatin Analog II-11

Other Pharmacological Therapeutic Agents II-11

3. PIPELINE OVERVIEW II-12

Select Pipeline Drugs in Diabetic Retinopathy Market II-12

An Overview of Select Pipeline Drugs II-13

Arxxant (Eli Lilly) II-13

Iluvien® (pSivida Corp.) II-13

Atacand (AstraZeneca) II-13

Lucentis (Genentech and Novartis) II-14

Avastin (Genentech/Roche) II-14

Vitreosolve® (Vitreo Retinal Technologies) II-14

Posurdex (Allergan) II-15

Macugen (EyeTech) II-15

Cand5 (Opko Health, Inc.) II-15

PF-4523655 (Quark Pharmaceuticals/Pfizer) II-16

Intravitreal Triamcinolone Acetonide (Allergan) II-16

Peribulbar Triamcinolone Acetonide (Bristol Myers) II-16

Microplasmin (ThromboGenics N.V.) II-17

Aflibercept (Regeneron/Bayer) II-17

Sirolimus (MacuSight/Santen) II-18

iCo-007 (iCo Therapeutics) II-18

Other Drugs with Potential Benefits in DR Treatment II-19

4. DISEASE OVERVIEW II-20

Diabetes II-20

Quick Facts on Diabetes II-20

Diabetic Retinopathy II-20

Leading Cause of Blindness in Diabetic Population II-21

Pathogenesis of Diabetic Retinopathy II-21

Clinical Features II-22

Proliferative and Non-Proliferative Diabetic Retinopathy II-22

Diabetic Macular Edema II-23

Risk Factors for the Condition II-23

Symptoms II-25

Prevention of Diabetic Retinopathy II-26

Detection of Proliferative Retinopathy and Macular Edema II-26

Visual Acuity Test II-26

Fundus Fluorescein Angiography II-27

Ophthalmoscopy II-27

Optical Coherence Tomography II-27

Non-Mydriatic Fundus Photography II-27

Dynamics of Evaluating Technologies II-28

Frequency of Examinations II-28

Treatment for Diabetic Retinopathy II-29

Laser Surgery II-29

Scatter Laser Treatment/ Panretinal Photocoagulation II-29

Focal Laser Treatment/ Photocoagulation II-30

Vitrectomy II-30

Kenalog/ Triamcinolone Actinomide II-31

5. RECENT INDUSTRY ACTIVITY II-32

Sanofi-Aventis to Take Over Fovea Pharmaceuticals II-32

New Injectable Steroid In-Line from Wakamoto Pharmaceutical II-32

Sirion Therapeutics and Advanced Vision Research Signs Agreement II-33

ActiveSite Develops Protease Inhibitor for Treating Diabetic

Retinopathy II-33

Pipex Acquires Global License for Additional Usage of Oral

Flupirtine II-34

MacuSight and Santen Ink License Agreement II-34

OptiMedica Enters into Distribution Agreement with Topcon Medical II-35

Lpath Submits IND for iSONEP(TM) II-35

Iris Pharma Merges with Clirophtha II-36

Isis Receives Milestone Payment for Initiating Trials of iCo-007 II-36

Eli Lilly Withdraws Marketing Authorization Application for

Arxxant in Europe II-37

ThromboGenics Begins Phase IIb Trial of Microplasmin in the US II-37

6. FOCUS ON SELECT GLOBAL PARTICIPANTS II-38

Allergan, Inc. (US) II-38

AstraZeneca PLC (UK) II-38

Eyetech, Inc. (US) II-38

Fovea Pharmaceuticals SA (France) II-39

Genentech, Inc. (US) II-39

Gene Signal (Switzerland) II-39

Isis Pharmaceuticals, Inc. (US) II-40

Lpath, Inc. (US) II-40

MacuSight, Inc. (US) II-41

OM PHARMA S.A (Switzerland) II-41

OPKO Health, Inc. (US) II-42

Oxford BioMedica Plc. (UK) II-42

pSivida Corp. (US) II-42

Quark Pharmaceuticals, Inc. (US) II-43

Sanwa Kagaku Kenkyusho Co., Ltd. (Japan) II-43

Sirnaomics, Inc. (US) II-44

Suzuken Co., Ltd. (Japan) II-44

Vitreoretinal Technologies, Inc. (US) II-44

7. US MARKET FORECASTS II-45

Table 4: US Diabetic Retinopathy Drugs Market Potential:

Annual Sales Forecasts in US$ Million for Years 2011 through

2015 (includes corresponding Graph/Chart) II-45

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 40 (including Divisions/Subsidiaries - 43)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 25

Canada 1

Japan 5

Europe 12

France 4

Germany 1

The United Kingdom 2

Rest of Europe 5

------------------------------------------

To order this report:

Pathology Industry: US Diabetic Retinopathy Industry

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Contact:

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Kiwanis, UNICEF JOIN FORCES TO SAVE 129 MILLION MO...
S
Reportlinker Adds Global Organ Preservation Soluti...